

# Zynerba Pharmaceuticals

08:59 01 Jul 2019

## Zynerba Pharmaceuticals joins Russell 3000 and Russell 2000 indexes

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) announced Monday that it has been added to the Russell 3000 and the Russell 2000 indexes.

The Russell 3000 Index is a market-capitalization-weighted equity index that gives investors exposure to the entire US stock market. The index tracks the performance of the 3,000 largest US-traded stocks, which represent about 98% of all US incorporated equity securities.

The Russell 2000 Index, also market-capitalization-weighted, measures the performance of 2,000 small-cap US companies in the Russell 3000 Index.

**READ:** Zynerba tells FDA it should regulate CBD and cannabis-derived products like standard pharmaceuticals  
 Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. About \$9 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

Zynerba, based in Devon, Pennsylvania, is currently developing Zysel, a CBD gel, to treat children aged three to 17 with Fragile X syndrome. Topline results are expected in the second half of 2019 from a clinical trial that evaluated the gel's potency and safety. The company also has started a trial to assess how Zysel can treat the pediatric behavioral and emotional symptoms of 22q11.2 Deletion Syndrome.


Contact the author: [patrick@proactiveinvestors.com](mailto:patrick@proactiveinvestors.com)

Follow him on Twitter @PatrickMGraham

**Price:** 4.26

**Market Cap:** \$98.82 m

### 1 Year Share Price Graph



February 2019 August 2019 February 2020

### Share Information

**Code:** ZYNE

**Listing:** NASDAQ

<b>52 week</b>	<b>High</b>	<b>Low</b>
	16.46	3.76

**Sector:** Pharma & Biotech

**Website:** [zynerba.com](http://zynerba.com)

### Company Synopsis:

*At Zynerba Pharmaceuticals, our team is dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for patients affected by rare and near-rare neuropsychiatric conditions. Often, these diseases have few, if any, treatment options and can leave patients and their families feeling helpless and alone.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Zynerba Pharmaceuticals named herein, including the promotion by the Company of Zynerba Pharmaceuticals in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to  
Twenty Five Thousand dollars (\$25,000).